CareerCross uses cookies to enhance your experience on our websites. If you continue to view our sites without changing your browser settings, then it is assumed that we have your consent to collect and utilise your cookies. If you do not want to give us your consent, then please change the cookie settings on your browser. Please refer to our privacy policy for more information.
CareerCross uses cookies to enhance your experience on our websites. If you continue to view our sites without changing your browser settings, then it is assumed that we have your consent to collect and utilise your cookies. If you do not want to give us your consent, then please change the cookie settings on your browser. Please refer to our privacy policy for more information.
Optieum Biotechnologies Inc.
Company Description
Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers.
Our proprietary platform technology, Eumbody System™, enables to develop and detect a scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.
We are committed to help patients with severe diseases by bringing life-changing therapies to the patients in need.
Eumbody System™
Optieum Biotechnologies’s Eumbody System™ is a proprietary platform technology for the development of next-generation scFv antibody.
Our technology enables to generate the new scFv expressing CAR-T cells with greater proliferation capacity and longevity, enabling superior reactivity against advanced tumors and minimized adverse effects.
We are open for a partnership to jointly develop a next generation immuno-oncology products.
Company Details
- Head Office
- Japan
- Main Business
- バイオ医薬品
- President
- 西岡 駿
- Established
- 2020 年 6 月 30 日
- URL
- https://optieumbio.com/#main
Offices
- Main Office
-
454 Shitsukawa, Toon-shi
Ehime, Japan, 7910204
